SEPARATION AND SETTLEMENT AGREEMENT BY AND BETWEEN ACTINIUM PHARMACEUTICALS, INC. AND DRAGAN CICICSeparation and Settlement Agreement • August 4th, 2017 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Separation and Settlement Agreement (“Agreement”), dated as of May 12, 2017 (the “Effective Date”), is made by and between Actinium Pharmaceuticals, Inc., a Delaware company (“Actinium” or the “Company”), and Dragan Cicic (“Employee”).
AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • August 4th, 2017 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations
This Agreement amends and restates in its entirety that certain Office Space License Agreement, dated as of March 10, 2016 and effective as of January 1, 2016, between Relmada and Actinium (the “Original Agreement”) for office space within the Premises. This Agreement is intended to and does completely amend and restate the Original Agreement.
ContractAssignment and Consent Agreement • August 4th, 2017 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS ASSIGNMENT AND CONSENT AGREEMENT (this “Agreement”), made as of the 6th day of June, 2017, between 275 MADISON AVENUE RPW 1 LLC and 275 MADISON AVENUE RPW 2 LLC, having an office in care of RPW Group, Inc., 800 Westchester Avenue, Rye Brook, New York 10573, hereinafter referred to collectively as the “Owner,” RELMADA THREAPEUTICS, INC., having an office at 275 Madison Avenue, Suite 702, New York, New York 10016, hereinafter referred to as the “Assignor,” and ACTINIUM PHARMACEUTICALS, INC., having an office at 275 Madison Avenue, Suite 702, New York, New York 10016, hereinafter referred to as the “Assignee.”
ACTINIUM PHARMACEUTICALS, INC. Common Stock (par value $0.001 per share) Amended and Restated At-the-Market Market Issuance Sales AgreementOriginal Sales Agreement • August 4th, 2017 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
CONSULTING AGREEMENTConsulting Agreement • August 4th, 2017 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations
This Consulting Agreement (“Agreement”) is entered into on May 22, 2017 (the “Effective Date”) by and between Actinium Pharmaceuticals, Inc., a Delaware corporation with a business address at 275 Madison Avenue, 7th Floor, New York, NY 10016 (the “Company”), and Dragan Cicic (“Consultant”).
AGREEMENTAgreement • August 4th, 2017 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Agreement ("Agreement") is entered into by and between Sergio Traversa ("Director" or "you") and Actinium Pharmaceuticals, Inc. (the "Company" or “Actinium”), and confirms the agreement that has been reached with you in connection with your resignation as a director of the Company (together, the “Parties”).
